Herschorn, Sender, et al. “Cost-Effectiveness of Mirabegron Compared to Tolterodine ER 4 Mg for Overactive Bladder in Canada”. Canadian Urological Association Journal, vol. 11, no. 3-4, Apr. 2017, pp. 123-30, doi:10.5489/cuaj.4114.